The results of our study show that BRCA1/2 genetic testing is well accepted in a group of long-surviving patients with a previous diagnosis of breast and ovarian cancer, even more than 10 years after the first cancer diagnosis with 78% adherence. The gene discussed is BRCA1; the disease is ovarian cancer.